Table of Content

1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview

3. Market Dynamics
3.1. Market Definition
3.2. Key Drivers
3.2.1. Demand From Governments For Diagnosing Covid-19 Positive Patients
3.2.2. Rise In Demand For Non-Invasive Diagnosis
3.2.3. Growth In The Number Of Diseases
3.2.4. Funding For Research And Development
3.2.5. Technological Advancements In The Market
3.3. Key Restraints
3.3.1. High Capital Requirement
3.3.2. Lack Of High Complexity Testing Centers

4. Key Analytics
4.1. Key Investment Insights
4.2. Porter’S Five Force Analysis
4.2.1. Buyer Power
4.2.2. Supplier Power
4.2.3. Substitution
4.2.4. New Entrants
4.2.5. Industry Rivalry
4.3. Opportunity Matrix
4.4. Vendor Landscape
4.5. Regulatory Framework

5. Market By Technology
5.1. Polymerase Chain Reaction
5.1.1. Real Time Pcr
5.1.2. Digital Pcr
5.2. Isothermal Nucleic Acid Amplification Technology
5.3. Other

6. Market By Product
6.1. Assays
6.2. Instruments
6.3. Software

7. Market By Application
7.1. Infectious Disease
7.1.1. Respiratory
7.1.2. Hospital Acquired Infections
7.1.3. Sexually Transmitted Infections
7.1.4. Gastro Intestinal Infections
7.2. Oncology
7.3. Prenatal
7.4. Others

8. Market By End-User
8.1. Hospitals
8.2. Clinics
8.3. Diagnostics Centres
8.4. Others

9. Geographical Analysis
9.1. Europe
9.1.1. United Kingdom
9.1.2. Germany
9.1.3. France
9.1.4. Italy
9.1.5. Russia
9.1.6. Belgium
9.1.7. Poland
9.1.8. Rest Of Europe

10. Company Profiles
10.1. Abbott Laboratories
10.2. Abacus Diagnostica
10.3. Biom?rieux Sa
10.4. Biocartis Nv
10.5. Danaher Corporation
10.6. Diasorin Spa
10.7. Bio-Rad
10.8. F Hoffmann-La Roche Ag
10.9. Luminex Corporation
10.10. Hologic Inc
10.11. Mesa Biotech
10.12. Spartan Biosciences Inc
10.13. Quantumdx Group Ltd
10.14. Quidel Corporation
10.15. Qiagen Nv



List of Figures


Figure 1: Key Investment Insights
Figure 2: Porter’S Five Force Analysis
Figure 3: Value Proposition - Laboratory, Immunoassay, And Molecular Poc Diagnostic
Figure 4: Opportunity Matrix
Figure 5: Vendor Landscape
Figure 6: Europe Molecular Point Of Care Diagnostics Market, Growth Potential, By Technology, In 2018
Figure 7: Europe Molecular Point Of Care Diagnostics Market, By Polymerase Chain Reaction, 2019-2028 (In $ Million)
Figure 8: Europe Molecular Point Of Care Diagnostics Market, Growth Potential, By Pcr Technology, In 2018
Figure 9: Europe Molecular Point Of Care Diagnostics Market, By Real Time Pcr, 2019-2028 (In $ Million)
Figure 10: Europe Molecular Point Of Care Diagnostics Market, By Digital Pcr, 2019-2028 (In $ Million)
Figure 11: Europe Molecular Point Of Care Diagnostics Market, By Isothermal Nucleic Acid Amplification Technology, 2019-2028 (In $ Million)
Figure 12: Europe Molecular Point Of Care Diagnostics Market, By Other, 2019-2028 (In $ Million)
Figure 13: Europe Molecular Point Of Care Diagnostics Market, Growth Potential, By Product, In 2018
Figure 14: Europe Molecular Point Of Care Diagnostics Market, By Assays, 2019-2028 (In $ Million)
Figure 15: Europe Molecular Point Of Care Diagnostics Market, By Instruments, 2019-2028 (In $ Million)
Figure 16: Europe Molecular Point Of Care Diagnostics Market, By Software, 2019-2028 (In $ Million)
Figure 17: Europe Molecular Point Of Care Diagnostics Market, Growth Potential, By Application, In 2018
Figure 18: Europe Molecular Point Of Care Diagnostics Market, By Infectious Disease, 2019-2028 (In $ Million)
Figure 19: Europe Molecular Point Of Care Diagnostics Market, Growth Potential, By Infectious Disease, In 2018
Figure 20: Europe Molecular Point Of Care Diagnostics Market, By Respiratory, 2019-2028 (In $ Million)
Figure 21: Europe Molecular Point Of Care Diagnostics Market, By Hospital Acquired Infections, 2019-2028 (In $ Million)
Figure 22: Europe Molecular Point Of Care Diagnostics Market, By Sexually Transmitted Infections, 2019-2028 (In $ Million)
Figure 23: Europe Molecular Point Of Care Diagnostics Market, By Gastro Intestinal Infections, 2019-2028 (In $ Million)
Figure 24: Europe Molecular Point Of Care Diagnostics Market, By Oncology, 2019-2028 (In $ Million)
Figure 25: Europe Molecular Point Of Care Diagnostics Market, By Prenatal, 2019-2028 (In $ Million)
Figure 26: Europe Molecular Point Of Care Diagnostics Market, By Others, 2019-2028 (In $ Million)
Figure 27: Europe Molecular Point Of Care Diagnostics Market, Growth Potential, By End-User, In 2018
Figure 28: Europe Molecular Point Of Care Diagnostics Market, By Hospitals, 2019-2028 (In $ Million)
Figure 29: Europe Molecular Point Of Care Diagnostics Market, By Clinics, 2019-2028 (In $ Million)
Figure 30: Europe Molecular Point Of Care Diagnostics Market, By Diagnostic Centres, 2019-2028 (In $ Million)
Figure 31: Europe Molecular Point Of Care Diagnostics Market, By Others, 2019-2028 (In $ Million)
Figure 32: Europe Molecular Point Of Care Diagnostics Market, Regional Outlook, 2019 & 2028 (In %)
Figure 33: United Kingdom Molecular Point Of Care Diagnostics Market, 2019-2028 (In $ Million)
Figure 34: Germany Molecular Point Of Care Diagnostics Market, 2019-2028 (In $ Million)
Figure 35: France Molecular Point Of Care Diagnostics Market, 2019-2028 (In $ Million)
Figure 36: Italy Molecular Point Of Care Diagnostics Market, 2019-2028 (In $ Million)
Figure 37: Russia Molecular Point Of Care Diagnostics Market, 2019-2028 (In $ Million)
Figure 38: Belgium Molecular Point Of Care Diagnostics Market, 2019-2028 (In $ Million)
Figure 39: Poland Molecular Point Of Care Diagnostics Market, 2019-2028 (In $ Million)
Figure 40: Rest Of Europe Molecular Point Of Care Diagnostics Market, 2019-2028 (In $ Million)


List of Tables


TABLE 1: MARKET SNAPSHOT - MOLECULAR POINT OF CARE DIAGNOSTICS
TABLE 2: EMERGENCY USE AUTHORISATION FOR DIAGNOSTICS BY FDA
TABLE 3: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 4: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 5: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PCR TECHNOLOGY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 6: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PCR TECHNOLOGY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 7: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 8: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 9: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 10: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY APPLICATION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 11: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 12: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY INFECTIOUS DISEASE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 13: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 14: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 15: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 16: EUROPE MOLECULAR POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)